NYSE$CVSA

Covista Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Adtalem reported a revenue increase and a return to total enrollment growth, driven by the Growth with Purpose strategy.

Adtalem Global Education reported a 4.1% year-over-year increase in revenue, reaching $368.8 million for the first quarter of fiscal year 2024. The company also saw a 1.9% increase in total student enrollment. Diluted earnings per share were reported at $0.25, with adjusted EPS at $0.93, a 3.3% year-over-year growth. The company raised its fiscal year 2024 revenue and adjusted EPS guidance.

  • Revenue increased by 4.1% year-over-year to $368.8 million.
  • Total student enrollment grew by 1.9% year-over-year, reaching 81,073 students.
  • Diluted earnings per share were $0.25, and adjusted EPS was $0.93, up 3.3% year-over-year.
  • Fiscal year 2024 revenue guidance was raised to $1,470 million to $1,530 million, with adjusted EPS guidance raised to $4.25 to $4.45.

Headline financials

Total Revenue

$369M

Previous: $355M+4.0%
EPS (adj)

$0.93

Previous: $0.88+5.7%
Capital Expenditures

-$15M

Previous: -$5.55M-171.1%
Free Cash Flow

-$4.4M

Previous: -$3.36M-31.0%
Net Income

$10.6M

Previous: $2.19M+385.7%
Operating Income

$28.2M

Previous: $23.1M+22.1%
Gross Profit

$200M

Previous: $195M+2.7%
Cash & Equivalents

$262M

Previous: $328M-19.9%
Total Assets

$2.79B

Previous: $3B-6.7%
Stock-Based Comp

$7.46M

Previous: $6.15M+21.3%

Revenue & EPS history

Adtalem · Revenue · Quarterly

$369M

Q1 2024+4%vs Q1 2023
Beat estimate in 12 of 14 quarters(86%)
ActualEstimate

Revenue by segment

Adtalem · $369M total across 3 segments · Q1 2024

  • Chamberlain
    $143M+5.3%
  • Walden
    $142M+8.2%
  • Medical and Veterinary
    $84.6M-4.1%

Forward guidance

Adtalem raised its fiscal year 2024 outlook, anticipating revenue between $1,470 million and $1,530 million and adjusted earnings per share between $4.25 and $4.45.

Tailwinds

  • Revenue guidance raised from $1,460 million - $1,520 million to $1,470 million - $1,530 million.
  • Adjusted earnings per share guidance raised from $4.20 - $4.40 to $4.25 - $4.45.
  • Strategic transformation program achieved milestone with return to total enrollment growth.
  • Confidence in fiscal 2024 expectations increased.
  • Positioned to address healthcare provider shortages.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-0.7%

Avg return

Earnings day

-0.3%

Avg return

5 days after

+0.7%

Avg return

30 days after

43%

29 / 67 earnings

Positive

+22.8%

Q1 2013

Best reaction

-33.2%

Q1 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026+13.2%+10.2%+8.0%
Q2 2026-7.8%-14.2%-15.5%
Q1 2026-33.2%-31.2%-34.7%
Q3 2025+16.4%+11.9%+10.7%
Q2 2025+4.6%+7.5%-0.1%
Q1 2025+12.0%+8.7%+23.8%
Q4 2024-7.3%-2.1%-2.2%
Q3 2024+18.9%+24.8%+27.5%
Q2 2024-13.9%-17.5%-15.6%
Q1 2024+12.5%+16.6%+29.4%
Q4 2023-1.1%-4.0%-0.8%
Q3 2023+4.5%+2.0%+2.4%
Q2 2023+13.7%+3.1%+2.2%
Q1 2023+2.4%+6.9%-2.1%
Q4 2022-3.1%-2.6%-2.8%
Q3 2022+6.4%+10.9%+17.5%
Q2 2022-12.7%-16.0%-15.2%
Q1 2022-12.9%-6.0%-16.6%
Q4 2021+1.3%+0.3%+11.8%
Q3 2021-6.9%-8.3%-1.3%
Q2 2021+0.1%+0.9%-2.8%
Q1 2021+3.7%+11.0%+16.6%
Q4 2020-4.4%-6.5%-25.9%
Q3 2020+3.7%+9.8%+11.5%
Q2 2020+3.1%-3.0%-14.9%
Q1 2020-19.2%-16.8%-7.8%
Q4 2019-12.5%-14.6%-20.9%
Q3 2019-7.6%-9.0%-11.4%
Q2 2019-3.3%-3.6%-4.1%
Q1 2019+4.3%+10.7%+14.0%
Q4 2018-15.8%-13.5%-20.0%
Q3 2018-5.7%-3.0%+1.4%
Q2 2018+7.1%+3.7%+12.3%
Q1 2018-2.7%+1.1%+9.7%
Q4 2017+4.3%+4.0%+8.1%
Q3 2017-0.8%+5.0%+0.5%
Q2 2017-0.5%-3.0%+0.2%
Q1 2017+1.8%+1.5%+31.5%
Q4 2016+17.7%+11.8%+4.3%
Q3 2016+17.3%
Q2 2016-14.2%
Q1 2016-2.3%
Q4 2015-7.7%
Q3 2015-15.9%
Q2 2015-17.9%
Q1 2015+0.8%
Q4 2014-3.2%
Q3 2014+13.0%
Q2 2014-2.6%
Q1 2014+6.2%
Q4 2013-9.5%
Q3 2013-17.6%
Q2 2013+19.1%
Q1 2013+22.8%
Q4 2009-2.2%
Q4 2012-2.3%
Q3 2012-0.4%
Q2 2012-8.5%
Q1 2012-0.8%
Q4 2011+4.7%
Q3 2011-1.4%
Q3 2010-1.4%
Q2 2010+0.0%
Q2 2011+0.0%
Q4 2010-1.1%
Q1 2010-1.1%
Q1 2011-1.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro